FINWIRES · TerminalLIVE
FINWIRES

Tong Ren Tang Chinese Medicine Gets Registered to Sell Liver Pacifying Capsules in Hong Kong

By

Beijing Tong Ren Tang Chinese Medicine (HKG:3613) obtained a registration certificate allowing it to sell its Antelope Horn Powder Capsules in Hong Kong, according to a Tuesday bourse filing.

The Certificate of Registration of Proprietary Chinese Medicine was obtained from the Chinese Medicine Council of Hong Kong.

The capsules are mainly indicated for pacifying the liver and extinguishing wind, clearing the liver, improving vision, dissipating blood, and removing toxins, the medicine maker said.

Related Articles

Asia

CTBC Financial Unit to Issue NT$9.6 Billion Bonds in June

CTBC Financial (TPE:2891) unit CTBC Bank will issue NT$9.6 billion in perpetual non-cumulative subordinated financial debentures on June 4, according to a Monday Taiwan Exchange filing.Shares gained about 2% in Tuesday's late morning trade.The 50th series subordinated bonds will carry a fixed annual coupon rate of 4.5% and have no maturity date.The bonds will be issued at face value, with each debenture carrying a denomination of NT$10 million.Proceeds will be used to strengthen its capital structure and replenish working capital.CTBC Bank said the notes may be redeemed after seven years, subject to regulatory approval.

TPE:2891
Asia

COSCO Shippig Specialized Carriers Plans Bond Issue of Up to 5 Billion Yuan

COSCO Shipping Specialized Carriers (SHA:600428) plans to register for issuance up to 5 billion yuan in bonds with a maximum term of 20 years.Proceeds will be used for repaying debts, replenishing working capital, paying ship construction costs and other permitted purposes, according to a Tuesday filing with the Shanghai bourse.The registration is valid for two years.

SHA:600428
Asia

Infratil's Fiscal 2026 Total Proportionate EBITDAF Meets Expectations, Jefferies Says

Infratil's (ASX:IFT, NZE:IFT) fiscal 2026 total proportionate earnings before interest, tax, depreciation, amortization, and fair value adjustments (EBITDAF) of NZ$919.3 million was in line with consensus of NZ$918.3 million, Jefferies said in a note on Tuesday.The company's EBITDAF increased 170% in the fiscal year with contributions from new projects completed in March and April 2025. Development EBITDAF losses of NZ$70 million was better than expected.Infratil swung to a profit of NZ$0.558 per share in fiscal 2026 from a loss of NZ$0.315 a year earlier. Revenue for the 12 months ended March 31 was NZ$3.04 billion, compared with NZ$2.86 billion a year earlier.The investment firm retained its buy rating on Infratil and its price targets of AU$14.40 and NZ$17.30.Infratil's Australian and New Zealand shares were each down 6% in recent Tuesday trade.

ASX:IFTNZE:IFT